CHMP Chair discusses expectations and challenges for the future
For PRIME co-founder and spokesperson Tomas Salmonson, finding more efficient and ‘joined-up’ ways of developing medicines that treat unmet medical needs is fundamental to the successful future of advanced healthcare. Today, too few products reach their clinical potential, reflecting complex markets, changing legislation and wide differences in the influence of stakeholders.
Achieving great stakeholder co-operation and a harmonised approach to meeting ‘unmet needs’ is, therefore, a precursor to future progress. According to Salmonson, the PRIME scheme is attracting around nine requests per month, but it remains to be seen whether interest from large pharma will also materialise alongside its main targets of SMEs. Either way, he sees PRIME as part of a necessary wider movement towards a collaborative future, and one that could be particularly poignant in a post-Brexit world.
Click here to read the interview with Tomas Salmonson